NEW YORK (360Dx) – 2018 was a roller coaster ride for investors in diagnostic companies, as softness in the broader markets led to a more modest year-over-year gain in the share prices of Dx firms compared to a year ago.

The 360Dx Index grew more than 4 percent in 2018 compared to the previous year and outpaced the Dow Jones Industrial Average, which was down 6 percent for 2018; the Nasdaq Composite, which retreated 4 percent; and the Nasdaq Biotech, which shrank 9 percent.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.